Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So sorry to hear things like this.
The product is still availaqble on ebay. Not sure for how long.
As I mentioned before even at present ebay prices it is still cheap.
If taking 6 a day that is $ 2.92 a day which is less than a cup of coffee. As we all know Anatabloc does far more than a cup of coffee.
Anatabloc Petition
http://bit.ly/donotblockanatabloc
Open Letter on Anatabloc
http://www.urbandomesticdiva.com/2014/09/an-open-letter-to-fda-regarding.html
FDA Contact Information
DRUGINFO@FDA.HHS.GOV
http://www.fda.gov/AboutFDA/ContactFDA/default.htm
Fast Track Info
http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimportantnewtherapies/ucm128291.htm
excerpts....
Speeding the development and availability of drugs that treat serious diseases are in everyone's interest, especially when the drugs are the first available treatment or have advantages over existing treatments. The Food and Drug Administration (FDA) has developed three distinct and successful approaches to making such drugs available as rapidly as possible: Priority Review, Accelerated Approval, and Fast Track. Because each of these approaches implies speed, there can be confusion about the specific meaning of each and the distinctions among them.
The following summary describes each element, how they differ, and how they complement each other.
Fast Track
Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious diseases and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. Fast Track addresses a broad range of serious diseases.
Determining whether a disease is serious is a matter of judgment, but generally is based on whether the drug will have an impact on such factors as survival, day-to-day functioning, or the likelihood that the disease, if left untreated, will progress from a less severe condition to a more serious one. AIDS, Alzheimer’s, heart failure and cancer are obvious examples of serious diseases. However, diseases such as epilepsy, depression and diabetes are also considered to be serious diseases.
Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially superior to existing therapy.
Any drug being developed to treat or prevent a disease with no current therapy obviously is directed at an unmet need. If there are existing therapies, a fast track drug must show some advantage over available treatment, such as:
*Showing superior effectiveness
*Avoiding serious side effects of an available treatment
*Improving the diagnosis of a serious disease where early diagnosis results in an improved outcome
*Decreasing a clinically significant toxicity of an accepted treatment
A drug that receives Fast Track designation is eligible for some or all of the following:
* More frequent meetings with FDA to discuss the drug’s development plan and ensure collection of appropriate data needed to support drug approval
* More frequent written correspondence from FDA about such things as the design of the proposed clinical trials
* Eligibility for Accelerated Approval, i.e., approval on an effect on a surrogate, or substitute endpoint reasonably likely to predict clinical benefit
* Rolling Review, which means that a drug company can submit completed sections of its New Drug Application (NDA) for review by FDA, rather than waiting until every section of the application is completed before the entire application can be reviewed. NDA review usually does not begin until the drug company has submitted the entire application to the FDA, and
* Dispute resolution if the drug company is not satisfied with an FDA decision not to grant Fast Track status.
In addition, most drugs that are eligible for Fast Track designation are likely to be considered appropriate to receive a Priority Review. Fast Track designation must be requested by the drug company. The request can be initiated at any time during the drug development process. FDA will review the request and make a decision within sixty days based on whether the drug fills an unmet medical need in a serious disease.
Once a drug receives Fast Track designation, early and frequent communication between the FDA and a drug company is encouraged throughout the entire drug development and review process. The frequency of communication assures that questions and issues are resolved quickly, often leading to earlier drug approval and access by patients.
Accelerated Approval
When studying a new drug, it can take a long time - sometimes many years - to learn whether a drug actually provides real improvement for patients – such as living longer or feeling better. This real improvement is known as a “clinical outcome.” Mindful of the fact that obtaining data on clinical outcomes can take a long time, in 1992 FDA instituted the Accelerated Approval regulation, allowing earlier approval of drugs to treat serious diseases, and that fill an unmet medical need based on a surrogate endpoint.
A surrogate endpoint is a marker - a laboratory measurement, or physical sign - that is used in clinical trials as an indirect or substitute measurement that represents a clinically meaningful outcome, such as survival or symptom improvement. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.
Approval of a drug based on such endpoints is given on the condition that post marketing clinical trials verify the anticipated clinical benefit.
The FDA bases its decision on whether to accept the proposed surrogate endpoint on the scientific support for that endpoint. The studies that demonstrate the effect of the drug on the surrogate endpoint must be “adequate and well controlled” studies, the only basis under law, for a finding that a drug is effective.
Use of a surrogate can save valuable time in the drug approval process. For example, instead of having to wait to learn if a drug actually can extend the survival of cancer patients, the FDA might now approve a drug based on evidence that the drug shrinks tumors because tumor shrinkage is considered reasonably likely to predict a real clinical benefit. In this example, an approval based upon tumor shrinkage can occur far sooner than waiting to learn whether patients actually lived longer. The drug company will still need to conduct studies to confirm that tumor shrinkage actually does predict that patients will live longer. These studies are known as phase 4 confirmatory trials.
If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug. If the confirmatory trial does not show that the drug provides clinical benefit for patients, FDA has regulatory procedures in place that could lead to removing the drug from the market.
Priority Review
Prior to approval, each drug marketed in the United States must go through a detailed FDA review process. In 1992, under the Prescription Drug User Act (PDUFA), FDA agreed to specific goals for improving the drug review time and created a two-tiered system of review times – Standard Review and Priority Review.
Standard Review is applied to a drug that offers at most, only minor improvement over existing marketed therapies. The 2002 amendments to PDUFA set a goal that a Standard Review of a new drug application be accomplished within a ten-month time frame.
A Priority Review designation is given to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. A Priority Review means that the time it takes FDA to review a new drug application is reduced. The goal for completing a Priority Review is six months.
Priority Review status can apply both to drugs that are used to treat serious diseases and to drugs for less serious illnesses. The FDA goal for reviewing a drug with Priority Review status is six months.
The distinction between priority and standard review times is that additional FDA attention and resources will be directed to drugs that have the potential to provide significant advances in treatment.
Such advances can be demonstrated by, for example:
* evidence of increased effectiveness in treatment, prevention, or diagnosis of disease;
* elimination or substantial reduction of a treatment-limiting drug reaction;
* documented enhancement of patient willingness or ability to take the drug according to the required schedule and dose; or
* evidence of safety and effectiveness in a new subpopulation, such as children.
A request for Priority Review must be made by the drug company. It does not affect the length of the clinical trial period. FDA determines within 45 days of the drug company’s request whether a Priority or Standard Review designation will be assigned. Designation of a drug as “Priority” does not alter the scientific/medical standard for approval or the quality of evidence necessary.
SUMMARY
Fast Track, Accelerated Approval and Priority Review are approaches that are intended to make therapeutically important drugs available at an earlier time. They do not compromise the standards for the safety and effectiveness of the drugs that become available through this process.
These revitalized FDA drug review approaches have yielded tangible results in bringing safe and effective drugs to patients with serious diseases more quickly. For example, since 1996, 68 drugs for cancer therapies have received priority review and approval.
FDA reviewed Gleevec, a treatment for chronic myeloid leukemia, in four months. Shortened review times have also brought promising treatments to patients with HIV/AIDS more quickly. Kaletra for the treatment of HIV/AIDS was reviewed and approved in 3.5 months. Pegasys, a combination product for the treatment of Hepatitis C was approved for marketing in 4 months.
Fast Track, Accelerated Approval, and Priority Review have evolved over time. FDA has been vigilant in assuring that reducing the time necessary for drug development has not compromised the safety and effectiveness of drugs for patients with serious diseases.
Thank you. I have tried for years to post here with little success. Could you please keep posting to these people so they finally get it.
So when they go to e-cigs they realize it is not nicotine. When are we going to have ANATABINE VAPOR????????????????
Comment Link: http://www.ihaveuc.com/does-smoking-really-help-ulcerative-colitis/comment-page-2/#comment-1051227
Comment:
The substance in tobacco that probably ameliorates your Crohn's is anatabine. Until recently, it was available in the nutraceutical Anatabloc, which is now under FDA review. My doctor (also my friend) has told me of Crohn's cases that "blow up" when someone quits smoking, but he has suggested Anatabloc to a number of patients. Hopefully, it will be back on the market soon. You might also search UrbanDiva/Anatabloc Diaries; a blogger with Crohn's who swears by Anatabloc.
Somebody who follows iHaveUC just wrote a new commentt to
Does Smoking Really Help Ulcerative Colitis?.
Comment Link: http://www.ihaveuc.com/does-smoking-really-help-ulcerative-colitis/comment-page-2/#comment-960169
Author: Jim M
Comment:
I was diagnosed with colitis 23 years ago, three weeks after I quit smoking.
I wasn't able to keep off the cigarettes, and never put two and two together until I tried to quite again a couple of times. My first bout landed me in the hospital. The second and third were not as bad because my will-power wasn't as good those times.
Now I use a vaporizer to help me quit (and it works like a charm) but I still have to smoke two or three cigarettes a day, or the attacks get so bad I can't go to work or even leave the house. Apparently it isn't the nicotine that keeps the colitis in check, but something else in the smoke.
And it does keep it in check, completely.
It's not a perfect solution, but I was able to go from a couple of packs a day to 2-3 packs per month, and my colitis is under control.
Somebody who follows iHaveUC just wrote a new commentt to Does Smoking Really Help Ulcerative Colitis?.
Comment Link: http://www.ihaveuc.com/does-smoking-really-help-ulcerative-colitis/comment-page-2/#comment-961014
Author: Julie
Comment:
Jim M-- that's great news. I'm glad to know just 2 or 3 a day is all you need. I have a self-discipline problem when I am smoking. I tend to smoke upwards of 1/2 to a pack in 24 hours. I really need to cut back although I am so grateful it works because I couldn't leave the house otherwise!
Comment: IMHO she should have been more vocal from the get go.
The Urban Domestic Diva
September 19 at 4:46pm ·
.
Some of u may know I am a big Anatabloc user 4 my Crohn's. The FDA made the company unceremoniously take it off the market! I plan on making my voice heard by writing, and perhaps a petition. If u use Anatabloc for your health, lets get our voices heard! ?#?dontblockanatabloc? Tweet it! Scream it! Share it!
Even at that price it is cheap. If taking 6 a day that is $ 2.92 a day which is less than a cup of coffee. As we all know Anatabloc does far more than a cup of coffee.
Pawsman
Are you following your CRP levels? Nothing like Anatabloc but there are other things you can do to help. Read below. Ebay has from time to time great buys on Anatabloc. Not the bidding war type but straight out offers. Have to check each day to see deals.
Tart Cherry--Costco had dried version
http://www.lef.org/magazine/mag2013/jun2013_Anti-Inflammatory-Properties-of-Tart-Cherry_01.htm
Puritan Pride
1000 mg Red Tart Cherry
http://www.puritan.com/food-supplements-004/tart-cherry-extract-1000-mg-031548
See list here:
http://www.lef.org/magazine/mag2014/may2014_Testing-For-C-reactive-Protein-May-Save-Your-Life_01.htm
Dr. Alex Roher’s research interests involve the pathogenesis and pathophysiology of Alzheimer’s disease (AD) and Parkinson’s disease (PD). His investigations cover four fundamental areas: 1) The role of cardiovascular disease in the etiology and clinical evolution of AD with special emphasis on coronary, carotid, circle of Willis and leptomeningeal atherosclerotic lesions producing brain hypoperfusion and consequent dementia. The degree of arterial atherosclerosis is assessed by functional assays including transcranial Doppler ultrasonography, carotid duplex ultrasonography (including intima/media thickness ratio) and cardiac function appraised by echocardiography and ultrasound measurements of cerebral blood flow. In addition, functional assays of atherosclerotic pathology are combined with direct physical measurements and computer assisted analyses of postmortem vascular specimens from clinically assessed individuals with and without autopsy-confirmed AD. 2) Characterization of potential biomarkers for AD present in cerebrospinal fluid (CSF), plasma as well as in peripheral lymphocyte populations from PD in antemortem and postmortem specimens. It is expected that biomarker identification of groups of specific proteins, detected by state of the art proteomic technologies, will facilitate the clinical diagnosis of AD and PD and aid assessment of future drug and treatment regime efficacy. 3) Characterization of amyloid precursor protein (APP) and amyloid beta peptides and their biochemical processing in APP and presenilin gene-expressing transgenic animal models of AD. The aim of this project is to elucidate the physicochemical differences in APP and amyloid beta that exist between humans and rodents, since these paradigms are widely used in the characterization of amyloid pathophysiology and in measuring AD therapeutic drug efficacy. 4) Investigation of white matter alterations involved in the pathogenesis of AD. These studies entail ultrastructural and biochemical changes, as detected in the immediate postmortem brain by electron microscopy and proteomic analysis, that differentiate AD from non-demented individuals.
As seen on HBO's documentary: The Alzheimer's Project http://www.hbo.com/alzheimers/
Anatabloc believers tout supplement's benefits
http://hamptonroads.com/2014/08/anatabloc-believers-tout-supplements-benefits
Comments: I wonder if 15 per day is not the magical number. Stockpiling was and still is wise. Wonder what their CRP numbers are? My goal is under one.
Should have been 10-15................. Amazing the detail that the press reports on this trial.
The Food and Drug Administration’s (FDA) Food and Cosmetic Information Center (FCIC) has received your inquiry. Your inquiry has been assigned case number yntduit ;). Please retain this case number and reference it in future correspondence regarding this inquiry.
We will respond to your inquiry as soon as possible. However, response times may vary, due to public health priorities and the high volume of inquiries we receive.
We strive to provide the public with accurate and current information, which at times requires extensive research. Please be assured that we will respond as soon as possible.
Thank you for contacting FDA’s FCIC.
http://www.fda.gov/AboutFDA/ContactFDA/default.htm
Can you supply a url where one does this? Thank you
Sports Inflammation Injuries
http://tinyurl.com/lxb33aq
I have tried and tried to communicate with those people and they just cannot connect the dots. Since they cannot purchase Anatabloc it is futile. They resort to smoking or other snake oil.
GNC has cancelled order for me on ebay after I paid. It took two weeks to get refund. Good Luck !!
Here is your proof that confirms your point about inflammation.
Inflammation is a disease
...according to the FDA
http://www.anh-usa.org/inflammation-disease/comment-page-1/#comments
Why? To make sure Big Pharma gets a monopoly on new drugs connected to it!
The FDA Calls One of the Body’s Basic Healing Functions a “Disease”
July 1, 2014
Why? To make sure Big Pharma gets a monopoly on new drugs connected to it!
Inflammation is the body’s complex biological response to harmful stimuli such as pathogens, irritants, or injuries. It’s a natural, protective attempt by the body to remove the stimuli and start the healing process. When this inflammation becomes too intense or chronic, the inflammatory response itself can damage tissues. Atherosclerosis, asthma, allergies, autoimmune disorders, celiac disease, rheumatoid arthritis, sarcoidosis, and even cancer are all triggered or caused by or involve inflammation.
Although it is a natural protective response of the human body, the FDA has decided that inflammation is, in and of itself, a disease, and that statements about the ability of a supplements to treat inflammation are “implied disease claims.” FDA issued at least ten warning letters in 2013 to companies for making alleged disease claims correlating dietary supplements to inflammation. Moreover, more than 150 companies—many in the practitioner channel—also received warnings from FDA in the early months of 2013 demanding that the companies discontinue all product claims related to inflammation. Based on these actions, the agency may consider any mention of “inflammation” to be a disease claim.
A source told ANH-USA that the FDA rejected a supplement company’s pre-marketing application which said that the product “supports healthy inflammatory response.” Under the landmark Dietary Supplement Health and Education Act of 1994, supplements are allowed to make claims about how a supplement may affect the structure and function of the body (“structure/function” claims), and this statement would seem to fall squarely in the structure/function category—but that’s not how the FDA is treating it.
Why is the FDA doing this? Because Big Pharma has some anti-inflammatory drugs in the pipeline, and they want a monopoly on its treatment. So they pressure the FDA, which receives an inordinate percentage of its operating budget from the pharmaceutical industry, and the FDA issues its warning letters. Here are just a few of the products being developed:
Five new drugs for inflammatory bowel disease, together with four new applications for existing drugs, are currently under investigation.
The FDA just approved Entyvio, which treats inflammation connected to Crohn’s disease.
Pharmaceutical company Gilead has nine drugs in various stages of clinical trials for inflammation in relation to cancer. Two of them have already been submitted to US and EU regulatory agencies for approval.
Evidence from clinical trials suggests that statin drugs, which claim to treat high cholesterol, are also anti-inflammatory. If statins gain new traction as anti-inflammatory drugs, drug companies may have found an additional way to further reduce competition from supplements. Of course, as our readers know, statins come with serious side effects, such as muscle pain and depletion of the vital heart nutrient CoQ10. Since the heart is a muscle and depends on CoQ10, the current rise in heart failure could well be linked to statin use.
Whatever the prospective merits or demerits of these drugs, inflammation is not an abnormal “disease” state of the body. It’s part of the body’s underlying maintenance system, and can be triggered by something as simple as stubbing your toe. By the FDA’s ludicrous definition, we wonder if the inflammation that results from stubbing your toe would be considered a disease too!
Even though I have enough to last a couple years I stopped by a GNC last night and tried to purchase four bottles that were in the back room with letter attached to them. I was not successful.
I got a copy of the letter dated August 11, 2014. "HOLD IN BACK ROOM ANATABLOC PRODUCTS" Please keep in back room until further notice.
"They need to go after the primary benefit, anti-inflammation, and stop playing games by going after the byproducts of the disease. I would gather the anti-inflammatory market is a multibillion dollar business, so they should quit f#cking around with the fancy leverage game."
Yes and the way they do the above is that it reduces "C-Reactive Protein" Everyone is looking for a fix to reduce CRP---the measure of body inflammation. You are dead on in the above statement.
If anatabine were supplied to e cigs we would be able to purchase vapor. That would be alternative. Missed opportunity. Not sure when they are going to figure out the opportunity in e cigs. All they would do is collect a royalty. How difficult would that be?
Congrats !! Most of the stores I have contacted have pulled the product.
After hours stock down to $ .31. Company has handled this horribly. We are always the last to know anything.
Rush to GNC Retail asap.
Firm halting sales of dietary supplement Anatabloc
Firm at center of trial involving former Virginia governor halts sales of dietary supplement
Associated Press
By Michael Felberbaum, AP Business Writer 4 minutes ago
0 shares
RICHMOND, Va. (AP) -- The dietary supplement maker at the center of a federal trial of former Virginia Gov. Bob McDonnell and his wife says it's halting sales of its product called Anatabloc.
Rock Creek Pharmaceuticals Inc. said Monday it is voluntarily stopping sales while it sorts out issues with the Food and Drug Administration.
Last year, the federal agency sent a warning letter to the company known as Star Scientific saying that its products contain a new dietary ingredient that requires approval before it can be marketed.
The agency also said the company's website had improperly promoted Anatabloc as a drug by suggesting it can be used to treat various diseases.
The McDonnells are charged with accepting gifts and loans from Star Scientific's former CEO in exchange for promoting his products.
The Black Box has always been who is producing the product? Third party? What kind of margins are they making. I always wondered why the company was not producing themselves. The shorts are the ones who know everything. We are always the last to hear. Welcome to our world !!
Sure glad I stocked up ahead of time. Perhaps the value of the product has now doubled. I guess we should raid all GNC stores today to buy everything.
In today's jury trial I expect a bombshell about McDonnell's dog getting a ride in Williams car. You heard it here first. Virginia press loves a blow by blow account. Every politician in this country needs to be worried of what is going on in Virginia.
Right on !! You would have thought they would have capitalized on this long ago. Cash cow. Instead of this they do a $ 299 face cream that only two people can afford.
"they could be selling anatbloc to ecig companies - would only take a few calls as there are an abundance of companies dying to have a eliquid that differentiates from the masses. in relation to the tobacco patents they could buy a manufacturing plant and start selling safe cigs."
time release abloc tabs or ecigs both game changers but never addressed.
Who purchased the 36 + million that traded on 6/27/14? I would have thought the shorts would have covered. Perhaps they did to cover some of their "naked" shorts.
Wow Unflavored 11 bottles at $46 bottle tinyurl.com/nqgrbwb
This is cheapest I have seen.
Hopefully us in a month. Take us over.
http://finance.yahoo.com/q?s=IDIX
Patrick Cox presentation --Half way through talks about inflammation and anatabine---excellent
http://www.mauldineconomics.com/landing/the-curse-of-the-alchemist-2
Go to a Vapor Shop to see the future. See how they are exploding in popularity. No tobacco is sold in Vapor shops. None.
Why is not Star selling anatabine to Vapor manufacturers? Makes no sense at all.
http://synergyvapor.com/
https://www.allaboutvapor.com/vaporshop3/
http://austinot.com/all-about-vapor
Sales to GNC are at average of $ 34. Look at cost of goods per 10K which is about $ 20 per bottle which is very high.
IF we had but ONE E cig deal shorts would have been long gone.
barbara.peters-smith@heraldtribune.com
http://health.heraldtribune.com/2013/02/25/test-can-measure-your-brain-reserve/
Positive numbers for a whole-body approach to lowering dementia risk
http://health.heraldtribune.com/2011/11/08/roskamp-institute-research-could-help-veterans/
Roskamp Institute research could help veterans
http://health.heraldtribune.com/2013/02/25/a-different-more-hopeful-way-of-looking-at-alzheimers/
A different, more hopeful way of looking at Alzheimer's
By Barbara Peters Smith , Herald-Tribune
/ Monday, February 25, 2013
In the two and a half years I've been writing about health and aging — and gosh, they've gone by fast — perhaps no field of medical research has seen as much dynamic change as the quest to find solutions for the crippling worldwide epidemic of Alzheimer's disease.
The reason for the explosion in diagnoses is pretty simple: We're living longer, and since Alzheimer's is a progressive affliction, our chances of developing full-blown symptoms zoom upward as we age. If you're 65, those chances are one in 10; and past your 85th birthday, the odds are almost 50 percent, according to the Alzheimer's Association.
After a decade of false starts and crushed hopes, researchers are enjoying some breakthroughs in both insights and funding. The Obama administration has made solving the Alzheimer's puzzle a priority, just as different strands of science are coming together to help explore the relationships between genetics, lifestyle, medical conditions and, yes, head injuries, that determine whether an individual's brain develops the plaques, tangles and frontal lobe erosions that are a hallmark of the disease.
The fascinating part is that, while neurologists have learned that the disease process begins much earlier than they once thought, evidence is building that there are ways for the brain to resist developing Alzheimer's.
I spoke recently with Mike Mullan, director since 2003 of Sarasota's Roskamp Institute, about science's twisted journey from the day when elders with dementia were thought to be "senile," or suffering from "hardening of the arteries."
"We spent a lot of time, 20 years ago, medicalizing Alzheimer's and making it not just a part of old age," he said. "Then, once we medicalized it, we said, 'We don't have any treatments.' So now we're rewriting the script to say, you know, there's an awful lot you can do."
He hopes the message will spread to primary care doctors, who have been frustrated by their inability to offer patients much more than a grim diagnosis.
"They have this feeling of impotence," he said. "They don't like dealing with dementia patients because they don't have effective medications they can give them."
Mullan said the institute is partnering in a new venture to promote brain health, called Sci-Brain, in part because Americans' fears surrounding Alzheimer's have opened the doors to crackpots, charlatans and junk science.
"The critical thing is to differentiate this from the nonspecific noise and disinformation that is out there all the time," he said. "It's very embarrassing to me as a scientist. There are doctors who argue way beyond any of the data."
As an example, Mullan cited claims that a choline-rich diet — emphasizing foods like egg yolks and soybeans — will keep your memory sharp.
"This is first-rate nonsense," he said. "If it were that easy, we'd all be modulating our neurotransmitters all the time just by putting certain foods into our brains. The reality is that nobody knows exactly what you have to do to increase the connections between neurons."
But Mullan said knowledge about what keeps those connections supple and active is increasing all the time.
"What we do know is that, in general, across a wide range of activities," some lifestyle changes solidly contribute to brain health, he said. "Maybe 10 years from now, we'll look at it and see what's really changed."
Agree. Have you ever reviewed the Tweets of Life Extenstion?
They are very agressive. https://twitter.com/LifeExtension
Not saying I have a problem with it. Just wish it was a level playing field.
What are your thoughts regarding the FDA response? Thanks
Yasiel Puig suffering inflammation on right shoulder
http://msn.foxsports.com/mlb/story/report-shoulder-inflammation-puts-dodgers-puig-on-limited-throwing-program-021314